Venetoclax plus chemo to treat certain AML types
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of venetoclax with liposome chemotherapy (daunorubicin and cytarabine) for adults with acute myeloid leukemia (AML) that is back after treatment or not responding, and for some newly diagnosed cases. It aims to shrink leukemia and help more people achieve remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older, and in one group (newly diagnosed) you must be 69 or younger
- Your AML must be relapsed or refractory (not responding) for most groups; a separate group is for newly diagnosed patients who have had no AML treatment
- Your heart pumping function (ejection fraction) must be at least 45% within the last 3 months
- Your liver and kidney lab tests must be within allowed ranges (bilirubin and AST/ALT limits; creatinine up to 1.5 times normal)
- Your overall health and daily functioning must be limited (ECOG 0–2)
- You must be able to consent and follow the study; pregnancy is not allowed during the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
Hear when a new Recurrent Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.